Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-label, Randomized, Active-controlled Study Comparing the Efficacy and Safety of Once Daily Enfuvirtide Dosing Versus the Currently Recommended Twice Daily Dosing in HIV-1 Infected Treatment-experienced Patients.

NCT00089492 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00089492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00089492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-label, Randomized, Active-controlled Study Comparing the Efficacy and Safety of Once Daily Enfuvirtide Dosing Versus the Currently Recommended Twice Daily Dosing in HIV-1 Infected Treatment-experienced Patients.
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2004
Completion date
June 30, 2006
Enrollment
64 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections